Tags

Type your tag names separated by a space and hit enter

Carvedilol, a new beta-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils.
Eur J Pharmacol. 1992 Apr 22; 214(2-3):277-80.EJ

Abstract

Carvedilol produced a dose-dependent inhibition of superoxide (O2-) release from human neutrophils (PMNs) (IC50 = 28 microM) and scavenged O2- generated during dihydroxyfumaric acid (DHF) autooxidation (IC50 = 41 microM). Other beta-blockers, such as celiprolol, labetalol and atenolol, or the antioxidant, 'lazaroid', U74500A had no effect on O2- either released from PMNs or generated during DHF autooxidation. Propranolol, at 0.3 mM, inhibited O2- release from PMNs (73%) but failed to scavenge O2- generated from DHF. The novel free radical-scavenging effect of carvedilol may contribute to the cardioprotective activity of the compound.

Authors+Show Affiliations

Department of Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406-0939.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

1355437

Citation

Yue, T L., et al. "Carvedilol, a New Beta-adrenoceptor Antagonist and Vasodilator Antihypertensive Drug, Inhibits Superoxide Release From Human Neutrophils." European Journal of Pharmacology, vol. 214, no. 2-3, 1992, pp. 277-80.
Yue TL, McKenna PJ, Ruffolo RR, et al. Carvedilol, a new beta-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils. Eur J Pharmacol. 1992;214(2-3):277-80.
Yue, T. L., McKenna, P. J., Ruffolo, R. R., & Feuerstein, G. (1992). Carvedilol, a new beta-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils. European Journal of Pharmacology, 214(2-3), 277-80.
Yue TL, et al. Carvedilol, a New Beta-adrenoceptor Antagonist and Vasodilator Antihypertensive Drug, Inhibits Superoxide Release From Human Neutrophils. Eur J Pharmacol. 1992 Apr 22;214(2-3):277-80. PubMed PMID: 1355437.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Carvedilol, a new beta-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils. AU - Yue,T L, AU - McKenna,P J, AU - Ruffolo,R R,Jr AU - Feuerstein,G, PY - 1992/5/2/pubmed PY - 2001/3/28/medline PY - 1992/5/2/entrez SP - 277 EP - 80 JF - European journal of pharmacology JO - Eur J Pharmacol VL - 214 IS - 2-3 N2 - Carvedilol produced a dose-dependent inhibition of superoxide (O2-) release from human neutrophils (PMNs) (IC50 = 28 microM) and scavenged O2- generated during dihydroxyfumaric acid (DHF) autooxidation (IC50 = 41 microM). Other beta-blockers, such as celiprolol, labetalol and atenolol, or the antioxidant, 'lazaroid', U74500A had no effect on O2- either released from PMNs or generated during DHF autooxidation. Propranolol, at 0.3 mM, inhibited O2- release from PMNs (73%) but failed to scavenge O2- generated from DHF. The novel free radical-scavenging effect of carvedilol may contribute to the cardioprotective activity of the compound. SN - 0014-2999 UR - https://www.unboundmedicine.com/medline/citation/1355437/Carvedilol_a_new_beta_adrenoceptor_antagonist_and_vasodilator_antihypertensive_drug_inhibits_superoxide_release_from_human_neutrophils_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0014-2999(92)90130-V DB - PRIME DP - Unbound Medicine ER -